{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:08:51Z","timestamp":1788570531878,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["73305095007"],"award-info":[{"award-number":["73305095007"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010969","name":"Alzheimer Nederland","doi-asserted-by":"publisher","award":["LSHM20106"],"award-info":[{"award-number":["LSHM20106"]}],"id":[{"id":"10.13039\/501100010969","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Previous studies demonstrated increases in diagnostic confidence and change in patient management after amyloid-PET. However, studies investigating longitudinal outcomes over an extended period of time are limited. Therefore, we aimed to investigate clinical outcomes up to 9\u00a0years after amyloid-PET to support the clinical validity of the imaging technique.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We analyzed longitudinal data from 200 patients (<jats:italic>M<\/jats:italic><jats:sub>age<\/jats:sub>\u2009=\u200961.8, 45.5% female, <jats:italic>M<\/jats:italic><jats:sub>MMSE<\/jats:sub>\u2009=\u200923.3) suspected of early-onset dementia that underwent [<jats:sup>18<\/jats:sup>F]flutemetamol-PET. Baseline amyloid status was determined through visual read (VR). Information on mortality was available with a mean follow-up of 6.7\u00a0years (range\u2009=\u20091.1\u20139.3). In a subset of 108 patients, longitudinal cognitive scores and clinical etiological diagnosis (eDx) at least 1\u00a0year after amyloid-PET acquisition were available (<jats:italic>M<\/jats:italic>\u2009=\u20093.06\u00a0years, range\u2009=\u20091.00\u20137.02). VR\u2009\u2212\u2009and VR\u2009+\u2009patients were compared on mortality rates with Cox Hazard\u2019s model, prevalence of stable eDx using chi-square test, and longitudinal cognition with linear mixed models. Neuropathological data was available for 4 patients (mean delay\u2009=\u20093.59\u2009\u00b1\u20091.82\u00a0years, range\u2009=\u20091.2\u20136.3).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At baseline, 184 (92.0%) patients were considered to have dementia. The majority of VR\u2009+\u2009patients had a primary etiological diagnosis of AD (122\/128, 95.3%), while the VR\u2009\u2212\u2009group consisted mostly of non-AD etiologies, most commonly frontotemporal lobar degeneration (30\/72, 40.2%). Overall mortality rate was 48.5% and did not differ between VR\u2009\u2212\u2009and VR\u2009+\u2009patients. eDx at follow-up was consistent with baseline diagnosis for 92\/108 (85.2%) patients, with most changes observed in VR\u2009\u2212\u2009cases (VR\u2009\u2212\u2009\u2009=\u200914\/35, 40% vs VR\u2009+\u2009\u2009=\u20092\/73, 2.7%, <jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200926.03, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), who at no time received an AD diagnosis. VR\u2009+\u2009patients declined faster than VR\u2009\u2212\u2009patients based on MMSE (<jats:italic>\u03b2<\/jats:italic>\u2009=\u2009\u2009\u2212\u20091.17, <jats:italic>p<\/jats:italic>\u2009=\u20090.004), episodic memory (<jats:italic>\u03b2<\/jats:italic>\u2009=\u2009\u2009\u2212\u20090.78, <jats:italic>p<\/jats:italic>\u2009=\u20090.003), fluency (<jats:italic>\u03b2<\/jats:italic>\u2009=\u2009\u2009\u2212\u20091.44, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and attention scores (<jats:italic>\u03b2<\/jats:italic>\u2009=\u200916.76, <jats:italic>p<\/jats:italic>\u2009=\u20090.03). Amyloid-PET assessment was in line with <jats:italic>post-mortem<\/jats:italic> confirmation in all cases; two cases were VR\u2009+\u2009and showed widespread AD pathology, while the other two cases were VR\u2009\u2212\u2009and showed limited amyloid pathology.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In a symptomatic population, we observed that amyloid-status did not impact mortality rates, but is predictive of cognitive functioning over time across several domains. Also, we show particular validity for a negative amyloid-PET assessment, as these patients did not receive an AD diagnosis at follow-up.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-023-01351-1","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T10:02:23Z","timestamp":1701079343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical outcomes up to 9\u00a0years after [18F]flutemetamol amyloid-PET in a symptomatic memory clinic population"],"prefix":"10.1186","volume":"15","author":[{"given":"Lyduine E.","family":"Collij","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gill","family":"Farrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Zwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsmarieke","family":"van de Giessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke J. M.","family":"Rozemuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolande A. L.","family":"Pijnenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"Bouwman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"issue":"4","key":"1351_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"1351_CR2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","volume":"10","author":"H Barthel","year":"2011","unstructured":"Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer\u2019s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10(5):424\u201335.","journal-title":"Lancet Neurol"},{"issue":"9","key":"1351_CR3","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/jamaneurol.2018.1346","volume":"75","author":"A de Wilde","year":"2018","unstructured":"de Wilde A, van der Flier WM, Pelkmans W, Bouwman F, Verwer J, Groot C, et al. Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: the ABIDE project. JAMA Neurol. 2018;75(9):1062\u201370.","journal-title":"JAMA Neurol"},{"issue":"13","key":"1351_CR4","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321(13):1286\u201394.","journal-title":"JAMA"},{"issue":"1","key":"1351_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-016-0228-4","volume":"9","author":"MD Zwan","year":"2017","unstructured":"Zwan MD, Bouwman FH, Konijnenberg E, van der Flier WM, Lammertsma AA, Verhey FR, et al. Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. Alzheimers Res Ther. 2017;9(1):2.","journal-title":"Alzheimers Res Ther"},{"issue":"8","key":"1351_CR6","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","volume":"16","author":"GB Frisoni","year":"2017","unstructured":"Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, et al. Strategic roadmap for an early diagnosis of Alzheimer\u2019s disease based on biomarkers. Lancet Neurol. 2017;16(8):661\u201376.","journal-title":"Lancet Neurol"},{"key":"1351_CR7","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1007\/s00259-020-05120-2","volume":"48","author":"M Boccardi","year":"2021","unstructured":"Boccardi M, Dodich A, Albanese E, Gayet-Ageron A, Festari C, Ashton NJ, et al. The strategic biomarker roadmap for the validation of Alzheimer\u2019s diagnostic biomarkers: methodological update. Eur J Nucl Med Mol Imaging. 2021;48:2070\u201385.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"1351_CR8","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1007\/s00259-020-05187-x","volume":"48","author":"M Cotta Ramusino","year":"2021","unstructured":"Cotta Ramusino M, Perini G, Altomare D, Barbarino P, Weidner W, Salvini Porro G, et al. Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. Eur J Nucl Med Mol Imaging. 2021;48(7):2157\u201368.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1351_CR9","doi-asserted-by":"crossref","unstructured":"Jack CR Jr, Therneau TM, Lundt ES, Wiste HJ, Mielke MM, Knopman DS, et al. Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. Brain Commun. 2022;4(2):fcac017.","DOI":"10.1093\/braincomms\/fcac017"},{"issue":"3","key":"1351_CR10","doi-asserted-by":"publisher","first-page":"476","DOI":"10.2967\/jnumed.113.120618","volume":"54","author":"KA Johnson","year":"2013","unstructured":"Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association. J Nucl Med. 2013;54(3):476\u201390.","journal-title":"J Nucl Med"},{"issue":"3","key":"1351_CR11","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/JAD-170850","volume":"62","author":"WM van der Flier","year":"2018","unstructured":"van der Flier WM, Scheltens P. Amsterdam Dementia Cohort: Performing Research to Optimize Care. J Alzheimers Dis. 2018;62(3):1091\u2013111.","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"1351_CR12","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(9):2456\u201377.","journal-title":"Brain"},{"key":"1351_CR13","doi-asserted-by":"crossref","unstructured":"Rom\u00e1n GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia. Diagnostic criteria for research studies: Report of the NINDS\u2010AIREN International Workshop.\u00a0Neurology. 1993;43(2):250.","DOI":"10.1212\/WNL.43.2.250"},{"key":"1351_CR14","doi-asserted-by":"crossref","unstructured":"McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies. Third report of the DLB consortium.\u00a0Br J Psychiatry.\u00a02005;65(12):1863-72.","DOI":"10.1212\/WNL.65.12.1992-a"},{"issue":"S5","key":"1351_CR15","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1002\/ana.10570","volume":"54","author":"BF Boeve","year":"2003","unstructured":"Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol. 2003;54(S5):S15\u20139.","journal-title":"Ann Neurol"},{"key":"1351_CR16","doi-asserted-by":"crossref","unstructured":"Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Report of the NINDS-SPSP International Workshop.\u00a0Neurology. 1996;47(1):1\u20139.","DOI":"10.1212\/WNL.47.1.1"},{"issue":"3","key":"1351_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398.","journal-title":"J Psychiatr Res"},{"issue":"2","key":"1351_CR18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1136\/jnnp.73.2.126","volume":"73","author":"J Lindeboom","year":"2002","unstructured":"Lindeboom J, Schmand B, Tulner L, Walstra G, Jonker C. Visual association test to detect early dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry. 2002;73(2):126\u201333.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1351_CR19","doi-asserted-by":"crossref","unstructured":"Morris JC, Edland S, Clark C, Galasko D, Koss E, Mohs R, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology. 1993;43(12):2457.","DOI":"10.1212\/WNL.43.12.2457"},{"issue":"5","key":"1351_CR20","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/0001-6918(65)90024-7","volume":"24","author":"AR Jensen","year":"1965","unstructured":"Jensen AR. Scoring the Stroop test. Acta Psychol (Amst). 1965;24(5):398\u2013408.","journal-title":"Acta Psychol (Amst)"},{"key":"1351_CR21","doi-asserted-by":"publisher","unstructured":"Allen DN, Haderlie MM. Trail-Making Test. In The Corsini Encyclopedia of Psychology (eds I.B. Weiner and W.E. Craighead). 2010. https:\/\/doi.org\/10.1002\/9780470479216.corpsy1003.","DOI":"10.1002\/9780470479216.corpsy1003"},{"issue":"1","key":"1351_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol. 2012;123(1):1\u201311.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"1351_CR23","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1750-3639.2008.00147.x","volume":"18","author":"I Alafuzoff","year":"2008","unstructured":"Alafuzoff I, Arzberger T, Al-Sarraj S, Bodi I, Bogdanovic N, Braak H, et al. Staging of neurofibrillary pathology in Alzheimer\u2019s disease: a study of the BrainNet Europe Consortium. Brain Pathol. 2008;18(4):484\u201396.","journal-title":"Brain Pathol"},{"issue":"2","key":"1351_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/nen.0b013e3181633526","volume":"67","author":"I Alafuzoff","year":"2008","unstructured":"Alafuzoff I, Parkkinen L, Al-Sarraj S, Arzberger T, Bell J, Bodi I, et al. Assessment of alpha-synuclein pathology: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol. 2008;67(2):125\u201343.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"1351_CR25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00401-009-0485-4","volume":"117","author":"I Alafuzoff","year":"2009","unstructured":"Alafuzoff I, Thal DR, Arzberger T, Bogdanovic N, Al-Sarraj S, Bodi I, et al. Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe Consortium. Acta Neuropathol. 2009;117(3):309\u201320.","journal-title":"Acta Neuropathol"},{"issue":"11","key":"1351_CR26","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1001\/archneur.59.11.1764","volume":"59","author":"R Brookmeyer","year":"2002","unstructured":"Brookmeyer R, Corrada MM, Curriero FC, Kawas C. Survival following a diagnosis of Alzheimer disease. Arch Neurol. 2002;59(11):1764\u20137.","journal-title":"Arch Neurol"},{"issue":"6","key":"1351_CR27","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1136\/jnnp-2018-318820","volume":"90","author":"HFM Rhodius-Meester","year":"2019","unstructured":"Rhodius-Meester HFM, Tijms BM, Lemstra AW, Prins ND, Pijnenburg YAL, Bouwman F, et al. Survival in memory clinic cohort is short, even in young-onset dementia. J Neurol Neurosurg Psychiatry. 2019;90(6):726\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"1351_CR28","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/gps.3946","volume":"28","author":"S Todd","year":"2013","unstructured":"Todd S, Barr S, Roberts M, Passmore AP. Survival in dementia and predictors of mortality: a review. Int J Geriatr Psychiatry. 2013;28(11):1109\u201324.","journal-title":"Int J Geriatr Psychiatry"},{"key":"1351_CR29","unstructured":"Fostitsch J, Frings L, Boeker M, Hellwig S, Bormann T, Meyer P. Amyloid-PET in dementia diagnostics: longer survival of amyloid-positive patients. Soc Nuclear Med; 2017;58(supplement 1):1255."},{"issue":"2","key":"1351_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/jnnp-2016-313775","volume":"88","author":"AW Lemstra","year":"2017","unstructured":"Lemstra AW, de Beer MH, Teunissen CE, Schreuder C, Scheltens P, van der Flier WM, et al. Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2017;88(2):113\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"1351_CR31","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/mds.26666","volume":"31","author":"J Graff-Radford","year":"2016","unstructured":"Graff-Radford J, Lesnick TG, Boeve BF, Przybelski SA, Jones DT, Senjem ML, et al. Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. Mov Disord. 2016;31(7):989\u201394.","journal-title":"Mov Disord"},{"issue":"8","key":"1351_CR32","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1177\/1533317513504611","volume":"28","author":"TD Koepsell","year":"2013","unstructured":"Koepsell TD, Gill DP, Chen B. Stability of clinical etiologic diagnosis in dementia and mild cognitive impairment: results from a multicenter longitudinal database. Am J Alzheimers Dis Other Demen. 2013;28(8):750\u20138.","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"1","key":"1351_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40336-014-0098-3","volume":"3","author":"AM Catafau","year":"2015","unstructured":"Catafau AM, Bullich S. Amyloid PET imaging: applications beyond Alzheimer\u2019s disease. Clin Transl Imaging. 2015;3(1):39\u201355.","journal-title":"Clin Transl Imaging"},{"key":"1351_CR34","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.nicl.2016.11.008","volume":"13","author":"SW Seo","year":"2017","unstructured":"Seo SW, Ayakta N, Grinberg LT, Villeneuve S, Lehmann M, Reed B, et al. Regional correlations between [(11)C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort. Neuroimage Clin. 2017;13:130\u20137.","journal-title":"Neuroimage Clin"},{"key":"1351_CR35","doi-asserted-by":"publisher","unstructured":"Collij, LE, Salvad\u00f3, G, de Wilde, A, et al. Quantification of [18F]florbetaben amyloid-PET imaging in a mixed memory clinic population: The ABIDE project. Alzheimer's Dement. 2023;19:2397\u2013407. https:\/\/doi.org\/10.1002\/alz.12886.","DOI":"10.1002\/alz.12886"},{"key":"1351_CR36","doi-asserted-by":"crossref","unstructured":"Jonsson L, Tate A, Frisell O, Wimo A. The costs of dementia in europe: an updated review and meta-analysis. Pharmacoeconomics. 2023;41:59\u201375.","DOI":"10.1007\/s40273-022-01212-z"},{"key":"1351_CR37","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.dadm.2017.01.003","volume":"6","author":"A de Wilde","year":"2017","unstructured":"de Wilde A, van Maurik IS, Kunneman M, Bouwman F, Zwan M, Willemse EA, et al. Alzheimer\u2019s biomarkers in daily practice (ABIDE) project: Rationale and design. Alzheimers Dement (Amst). 2017;6:143\u201351.","journal-title":"Alzheimers Dement (Amst)"},{"key":"1351_CR38","doi-asserted-by":"publisher","unstructured":"Rabinovici GD, Carrillo MC, Apgar C, et al. Amyloid Positron Emission Tomography and Subsequent Health Care Use Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA Neurol. 2023;80(11):1166\u201373. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3490.","DOI":"10.1001\/jamaneurol.2023.3490"},{"key":"1351_CR39","doi-asserted-by":"crossref","unstructured":"Frisoni GB, Barkhof F, Altomare D, Berkhof J, Boccardi M, Canzoneri E, et al. AMYPAD diagnostic and patient management study: rationale and design. Alzheimers Dement. 2018;15:388\u201399.","DOI":"10.1016\/j.jalz.2018.09.003"},{"key":"1351_CR40","doi-asserted-by":"crossref","unstructured":"van Maurik IS, Broulikova HM, Mank A, Bakker ED, de Wilde A, Bouwman FH, et al. A more precise diagnosis by means of amyloid PET contributes to delayed institutionalization, lower mortality, and reduced care costs in a tertiary memory clinic setting. Alzheimers Dement. 2023;19:2006\u201313.","DOI":"10.1002\/alz.12846"},{"issue":"9","key":"1351_CR41","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/2041-210X.13434","volume":"11","author":"H Schielzeth","year":"2020","unstructured":"Schielzeth H, Dingemanse NJ, Nakagawa S, Westneat DF, Allegue H, Teplitsky C, et al. Robustness of linear mixed-effects models to violations of distributional assumptions. Methods Ecol Evol. 2020;11(9):1141\u201352.","journal-title":"Methods Ecol Evol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-023-01351-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-023-01351-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-023-01351-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T10:10:07Z","timestamp":1701079807000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-023-01351-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1351"],"URL":"https:\/\/doi.org\/10.1186\/s13195-023-01351-1","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"assertion":[{"value":"27 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the medical ethics review committee of the VU University Medical Center (reference number 2012\/302). All participants provided written informed consent to participate in the study. The study was conducted following the Protocol and the Declaration of Helsinki and Good Clinical Practice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/a.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Lyduine E. Collij has received research support from GE Healthcare and Springer Healthcare (paid by Eli Lilly). Both are paid to the institution.Gill Farrar is a full-time employee of GE Healthcare.Marissa Zwan reports no relevant disclosures.Elsmarieke van Giessen reports no relevant disclosures.Rik Ossenkoppele has received a speakers fee from GE Healthcare (paid to the institution) and receives research support from Avid Radiopharmaceuticals. RO is an editorial board member for the European Journal of Nuclear Medicine and Molecular Imaging and for Alzheimer\u2019s Research & Therapy.Frederik Barkhof received payment and honoraria from Bayer Genzyme, Biogen-Idec, TEVA, Merck, Novartis, Roche, IXICO Ltd, GeNeuro, and Apitope Ltd for consulting; payment from the IXICOLtd, and MedScape for educational presentations; research support via grants from EU\/EFPIA Innovative Medicines Initiative Joint Undertaking (AMYPAD consortium), EuroPOND (H2020), UK MS Society, Dutch MS Society, PICTURE (IMDI-NWO), NIHR UCLH Biomedical Research Centre (BRC), ECTRIMS-MAGNIMS.Annemieke Rozemuller reports no relevant disclosures.Yolande Pijnenburg reports no relevant disclosures.Wiesje M. van der Flier Research programs of Wiesje van der Flier have been funded by ZonMW, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Pasman stichting, stichting Alzheimer & Neuropsychiatrie Foundation, Biogen MA Inc, Boehringer Ingelheim, Life-MI, AVID, Roche BV, Fujifilm, Combinostics. WF holds the Pasman chair. WF is a recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). WF has performed contract research for Biogen MA Inc., and Boehringer Ingelheim. WF has been an invited speaker at Boehringer Ingelheim, Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), Springer Healthcare. WF is a consultant to Oxford Health Policy Forum CIC, Roche, and Biogen MA Inc. WF participated in advisory boards of Biogen MA Inc and Roche. All funding is paid to her institution. WF was associate editor of Alzheimer, Research & Therapy in 2020\/2021. WF is an associate editor at Brain.Femke Bouwman has research projects in cooperation with Optina Dx and Optos who paid to her institution Alzheimer Center, VU University Medical Center. She has received speaker\u2019s fees paid to the institution from Roche and Biogen.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"207"}}